X-DAX
13.162
-0,57%
Dow Jones
31.438
-0,20%
L-TecDAX
2.950
+0,97%
Dollarkurs
1,058
-0,06%
Aktien
News
Forum
Zertifikate
Hebelprodukte
Devisen
Rohstoffe
Fonds
ETFs
Krypto
Anleihen
Depot
Login
Ihre verpassten Browser Pushes der letzten 24 Stunden:
Tagesausblick für 28.06.: DAX kann Tageshoch erneut nicht halten. Wasserstoffaktien und Maschinenbauer gefragt!
Nasdaq 100 – Das erste Gap ist Geschichte
Bayer – Geschäfte laufen. Rechtsstreit bremst!
Alle löschen
Top-News
Breaking News! Kickt „Yumy Bear“ die Konkurrenz aus den Shops?(Anzeige)
27.06.22
G7 verurteilen Angriff auf Einkaufszentrum - 'Kriegsverbrechen'
27.06.22
US-Banken erhöhen nach Stresstest Aktienrückkäufe und Dividenden
27.06.22
GESAMT-ROUNDUP3: Einkaufscenter in Ukraine getroffen - G7 und Nato erhöhen Druck
27.06.22
Nike mit deutlich weniger Gewinn - Covid-Lockdowns in China belasten
27.06.22
ROUNDUP/Proteste in Niederlanden: Bauern blockieren Autobahnen
Startseite
Aktien
Savara Aktie
News
Depot
Watchlist
Jetzt für 0€ handeln
Savara News
1.57
1,58
$
+0,64%
+0,01 $
In
: 1,4937 € | 27.06.22 22:00:01 Nasdaq
aktualisieren
|
Orderbuch
|
Mehr Kurse
»
WKN: A2DQ2B
ISIN: US8051111016
US-Symbol:
SVRA
Typ: Aktie
Übersicht
Kurse
Chart
News
Forum
Alle Nachrichten
Top-News
ARIVA.DE Redaktion
Videos
Unternehmensmeldungen
Ad-hocs
Insider Trading
Analysen
Savara News
< Zurück
< Zurück
von 8
Weiter >
Weiter >
< Zurück
< Zurück
von 8
Weiter >
Weiter >
16.06.22
- Businesswire
Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced molgramostim has been awarded an ...
01.06.22
- Businesswire
Savara to Present at Jefferies Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the ...
17.05.22
- Businesswire
Savara to Present at H.C. Wainwright Global Investment Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the ...
11.05.22
- Businesswire
Savara Reports First Quarter 2022 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, ...
26.04.22
- Businesswire
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new ...
22.04.22
- Businesswire
Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it entered into a term loan agreement of ...
30.03.22
- Businesswire
Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, reported financial results for the fourth quarter and full year ending December 31, 2021 and provided a business ...
17.03.21
- PR Newswire
Thinking about buying stock in FSD Pharma, Onconova Therapeutics, Nabriva Therapeutics, Zosano Pharma, or Savara?
Thinking about buying stock in FSD Pharma, Onconova Therapeutics, Nabriva Therapeutics, Zosano Pharma, or Savara? PR Newswire
16.03.21
- PR Newswire
Thinking about buying stock in Can Fite, Zomedica, AMC Entertainment, Savara, or SunLink Health?
Thinking about buying stock in Can Fite, Zomedica, AMC Entertainment, Savara, or SunLink Health? PR Newswire
02.04.19
- ACCESSWIRE
Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London
AUSTIN, TX / ACCESSWIRE / April 2, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Rob Neville, Chief Executive Officer, will ...
13.03.19
- ACCESSWIRE
Savara Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update
On-Track to Report Top Line Results from Pivotal Phase 3 IMPALA Study at End of Q2 2019
06.03.19
- ACCESSWIRE
Savara To Report Q4/Year-End 2018 Financial Results And Business Update On March 13, 2019
AUSTIN, TX / ACCESSWIRE / March 6, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its fourth quarter and year-end 2018 ...
04.03.19
- ACCESSWIRE
Savara to Present at the 39th Annual Cowen and Company Healthcare Conference
AUSTIN, TX / ACCESSWIRE / March 4, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today that the company's Chief Executive Officer, Rob ...
11.07.17
- PR Newswire
Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension
Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension Aironite Significantly ...
20.06.17
- PR Newswire
Savara Set To Join Russell Microcap® Index
Savara Set To Join Russell Microcap® Index PR Newswire
07.06.17
- PR Newswire
Savara Announces Closing Of Public Offering Of Common Stock
Savara Announces Closing Of Public Offering Of Common Stock PR Newswire
05.06.17
- PR Newswire
Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th
Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th PR Newswire
02.06.17
- PR Newswire
Savara Announces Pricing Of Public Offering Of Common Stock
Savara Announces Pricing Of Public Offering Of Common Stock PR Newswire
01.06.17
- PR Newswire
Savara Announces Proposed Public Offering Of Common Stock
Savara Announces Proposed Public Offering Of Common Stock PR Newswire
10.05.17
- PR Newswire
Savara Announces Expedited U.S. Molgradex Development Strategy
Savara Announces Expedited U.S. Molgradex Development Strategy Ongoing IMPALA Study to be Expanded to Serve as Global Pivotal Study for Registration PR Newswire
< Zurück
< Zurück
von 8
Weiter >
Weiter >
Newssuche
Videos
27.06.22
Technical Trading - Kakao zum Monatsende Long
Kakao Long OE Turbo Bull Hebel: 7 WKN: VQ9A2K Kauforder: Market Gültigkeit: tagesgültig Stop-Loss: 0,5 € ...
Mehr »
Weitere Videos
Aktie im Fokus
Anzeige
Sommer-Jackpot?
Bettermood Food
0,6666
€
-6,55%
Spannendster Launch des Jahres: Reale Chance auf einen Kursvervielfacher?
Mehr zur Aktie »
Webinare im Juni
29.06.2022, 17:30 Uhr
ValuePlus – Die besten Aktien aus Fundamental- und Chartanalyse
Alle Webinare
Sommer-Jackpot?
Spannendster Launch des Jahres: Reale Chance auf einen Kursvervielfacher?
weiterlesen»
Anzeige
wo-site-teaser-box-10863_site-teaser-box_2022-06-27_10%253A00%253A00_2022-06-28_09%253A00%253A59
ARIVA weekly